RWC-340B rejected and Hemophilia Alliance criticized PhRMA and NACHC's joint plan to restructure the 340B program.
Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net
PhRMA has written an eight-page document that elaborates on its principles for 340B program reform.
A confidential document composed by Pharmaceutical Research and Manufacturers of America in connection with its 340B program reform initiative with the National Association of Community Health Centers fleshes out a “coalition” vision of the 10-point reform plan that
340B Health says, "For just the first five of the 21 drug companies for which there is a full year of data post-restrictions, the 340B savings for hospitals decreased by an estimated $1.1 billion from 2020 to 2021."
Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in
“There is no way for 340B to be fixed without everybody coming to the table,” PhRMA spokesperson Nicole Longo said in an interview with 340B Report.
The fallout continues from drug makers and health centers’ decision to work together to change the 340B program, with the drug industry giving its first interview about the deal to 340B Report on Friday and several hospital groups
Lt. Cmdr. Emeka Egwim (left), Director of HRSA's Office of Pharmacy Affairs, spoke this morning on 340B Day at NACHC's annual Policy & Issues Forum in Washington, D.C.
A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program.
PhRMA, NACHC, and and the National Hispanic Medical Association created a new group, ASAP 340B, and issued a 10-point plan to ensure that the 340B program “benefits patients and true safety-net providers, including rural hospitals.”
Pharmaceutical Research and Manufacturers of America, the National Association of Community Health Centers, and the National Hispanic Medical Association this morning jointly issued a 10-point plan and created a nonprofit group to ensure that the 340B program “benefits
Lilly's decision to cut the price of its fast-acting insulin Humalog might have been driven by a desire to avoid exposure to Medicaid rebates, drug pricing expert Sean Dickson says.
Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing